Roche Perjeta Wins Panel Backing for Early Breast Cancer

Roche Holding AG’s Perjeta won the backing of U.S. regulatory advisers to potentially become the first pre-surgical drug treatment for breast cancer that could lead to a less-invasive procedure.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.